Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

a0F4X00000cdWQrUAM - ESMO24 CDK4+CDK2 Ph1 Oral

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

PHASE 1B/2 FIRST-IN-CLASS NOVEL COMBINATION TRIAL OF NEXT GENERATION CDK4-SELECTIVE INHIBITOR PF-07220060 AND NEXT GENERATION CDK2-SELECTIVE INHIBITOR PF-07104091 IN HR+ HER2- METASTATIC BREAST CANCER AND ADVANCED SOLID TUMORS

/sites/default/files/scientific_presentation/ESMO24_CDK4_CDK2_Ph1.pdf